(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2014 (05.06.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/085527 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C12P 21/06* (2006.01)
C12N 15/63 (2006.01)

(21) International Application Number:
PCT/US2013/072137

(22) International Filing Date:
27 November 2013 (27.11.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/731,368 29 November 2012 (29.11.2012) US

(71) Applicant: **BAYER HEALTHCARE LLC** [US/US]; 555 White Plains Rd., Tarrytown, NY 10591 (US).

(72) Inventors: **ZHAO, Xiao-yan**; 5075 Anaheim St., Union City, CA 94587 (US). **WANG, Zhuozhi**; 1388 Broadway, Unit 383, Millbrae, CA 94030 (US). **KIM, Ji-Yun**; 1168 Besito Ave., Berkeley, CA 94705 (US). **ZHU, Ying**; 3150 Stone Valley Rd., Alamo, CA 94507 (US). **TEBBE, Jan**; Am Alten Stellwerk 16, 50733 Cologne (DE).

(74) Agent: **HIGHLANDER, Steven L.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

[Continued on next page]

(54) Title: HUMANIZED MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C AND USES THEREOF

(57) Abstract: Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.




FIG. 1

WO 2014/085527 A1

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*